Jean-Paul Clozel, Idorsia CEO (AP Images)
October 11, 2021 07:19 AM EDTUpdated 08:45 AM
R&D

Idor­si­a's Fab­ry dis­ease pro­gram flops a PhI­II study, leav­ing its fu­ture un­clear

Max Gelman

Senior Editor

A top pro­gram for Swiss biotech Idor­sia faces a murky fu­ture af­ter flunk­ing a Phase III test.

Idorisa’s drug can­di­date for Fab­ry dis­ease, known as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times